Education
About Us
Working with TipRanks
Follow Us
Oxford Biomedica (otc) (OXBDF)
:OXBDF
OXBDF Stock Chart & Stats
$7.90
-$0.05(-0.85%)
At close: 4:00 PM EST
$7.90
-$0.05(-0.85%)
Day’s Range― - ―
52-Week Range$3.15 - $9.20
Previous CloseN/A
Volume1.00K
Average Volume (3M)3.47K
Market Cap
$930.28M
Enterprise Value$387.11M
Total Cash (Recent Filing)$53.88M
Total Debt (Recent Filing)$105.42M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Sep 23, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding120,538,820
10 Day Avg. Volume8,533
30 Day Avg. Volume3,474
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)7.62
Price to Sales (P/S)3.37
P/FCF Ratio-7.48
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit5.83
Enterprise Value/Ebitda-360.10
Forecast
1Y Price Target
$9.12Price Target Upside15.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Order BookThe company's contracted order book reached approximately £186m in 2024, representing over a 30% increase year-over-year.
Revenue GrowthOXB delivered revenues of £128.8m, in line with its January trading update and previous guidance, representing 44% growth YoY.
Bears Say
Macroeconomic HeadwindsThere is a level of caution on the outlook due to uncertain macroeconomic headwinds and a tight funding environment.
Oxford BioMedica News
OXBDF FAQ
What was Oxford Biomedica (otc)’s price range in the past 12 months?
Oxford Biomedica (otc) lowest stock price was $3.15 and its highest was $9.20 in the past 12 months.
What is Oxford Biomedica (otc)’s market cap?
Oxford Biomedica (otc)’s market cap is $930.28M.
When is Oxford Biomedica (otc)’s upcoming earnings report date?
Oxford Biomedica (otc)’s upcoming earnings report date is Sep 23, 2025 which is 91 days ago.
How were Oxford Biomedica (otc)’s earnings last quarter?
Oxford Biomedica (otc) released its earnings results on Apr 09, 2025. The company reported -$0.103 earnings per share for the quarter, the consensus estimate of -$0.103 by $0.
Is Oxford Biomedica (otc) overvalued?
According to Wall Street analysts Oxford Biomedica (otc)’s price is currently Undervalued.
Does Oxford Biomedica (otc) pay dividends?
Oxford Biomedica (otc) does not currently pay dividends.
What is Oxford Biomedica (otc)’s EPS estimate?
Oxford Biomedica (otc)’s EPS estimate is -0.27.
How many shares outstanding does Oxford Biomedica (otc) have?
Oxford Biomedica (otc) has 120,538,820 shares outstanding.
What happened to Oxford Biomedica (otc)’s price movement after its last earnings report?
Oxford Biomedica (otc) reported an EPS of -$0.103 in its last earnings report, expectations of -$0.103. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Oxford Biomedica (otc)?
Currently, no hedge funds are holding shares in OXBDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oxford BioMedica Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.12 (15.44% Upside)
$9.12 (15.44% Upside)
Insider Transactions
Sold Shares
Worth $306.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.13%
12-Months-Change
Fundamentals
Return on Equity
-74.64%
Trailing 12-Months
Asset Growth
-4.27%
Trailing 12-Months
Company Description
Oxford Biomedica (otc)
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
OXBDF Company Deck
OXBDF Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.View all OXBDF earnings summariesOXBDF Stock 12 Month Forecast
Average Price Target
$9.12
▲(15.44% Upside)
Technical Analysis
Avacta Group plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Oxford Nanopore Technologies PLC
―
Ownership Overview
Options Prices
Currently, No data available
---